Thank you so much to Sírio-Libanês for inviting me tonight to the 2024 Breast Cancer Excellence event. We discussed applications of #artificialintelligence in #healthcare , the #biases we should be aware of, and the #challenges ahead! #bcsm #digitalhealth #HealthEquity

As a society, we need to demand disclosure of relevant information about how foundation models, including large language models, are developed, evaluated and tested. The biggest risk associated with the use of AI is cementing structural inequities into our systems.

Dr. Heather Parsons, a thought leader in the field, discussed #ResidualDisease & HER2 Status in #BreastCancer at the Gustave Roussy/Dana-Farber Transatlantic Exchange on #LiquidBiopsy . She highlighted exciting new research such as the STOP-HER2 study and the SAPPHO study.

2y after our perspective, the first tissue-agnostic ADC approval is out!

Paolo Tarantino Roberto Pestana, MD G Curigliano MD PhD Sara Tolaney In 2022: Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?
In 2024: 🎊
pubmed.ncbi.nlm.nih.gov/35696887/

EHR giant Epic plans to release an AI validation software suite to enable healthcare organizations to evaluate AI models at the local level and monitor those systems over time.

fiercehealthcare.com/ai-and-machine…
#EHR #Epic #artificialintelligence #NLP

📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in JAMA

jamanetwork.com/journals/jama/…

Here's the latest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (March 25th-31st, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancer Research

Truly inspiring talk by Sarah Temkin at DF/HCC Breast & Gynecologic Cancer Symposium: “Why listening to women matters in ovarian cancer research”.
Dana-Farber’s Breast Oncology Center #disparities #equity
#bcsm Harvard Medical School

In patients with stage II or III early breast cancer, the addition of ribociclib to adjuvant hormonal therapy resulted in a significant improvement in 3-year invasive disease–free survival. Read the full results of the NATALEE phase 3 trial: nej.md/3IM24rq

Shaping the future of #AI in #healthcare through #ethics and governance nature.com/articles/s4159…

#FunMoment

Dear American friends ❤️, here’s a mini- #tutorial on how to pronounce my name (and all Italian 🇮🇹🍝names containing “CHI”):

-ARCHITECTURE
-ORCHID
-ZUCCHINI

-> CHIARA

(Giampaolo Bianchini you’re welcome! 😆)

Similar to what happened with ESMO - Eur. Oncology endorsing T-DXd for 2L in metastatic breast cancer guidelines. #bcsm

Hope regulatory agencies like EU Medicines Agency will be able to provide rapid #access to the best available treatment for our patients.

New ESMO - Eur. Oncology guidlines for advanced bladder cancer Annals of Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available annalsofoncology.org/article/S0923-…

The first of its kind European Parliament MIT Critical Data #artificialintelligence #innovation

Excellent presentations from Dana-Farber staff at the Miami #BreastCancer Conference #mbcc2024
👉Dr. Chiara Corti presented clinical cases at the tumor board session
👉Dr. Jennifer Bellon reviewed advances in #PBI
👉Dr. Clara Park discussed robotic-assisted #mastectomy

One of the very first talks about AI at a cancer conference that is not all hype but rigorously addresses all the #challenges we need to be aware of if we want to get AI to clinic. Kudos to Anant Madabhushi from Emory University

#artificialintelligence #MBCC2024 #bcsm MIT Critical Data

Extremely grateful for the opportunity to present challenging clinical cases during the Molecular Tumor Board session. Amazing experience here at the #MBCC2024 #MiamiBreast #MBCC24 #MTB #breastcancer #bcsm

Celebrate #InternationalWomensDay2024

📖' #Artificial #Intelligence for #Medicine ' will be available from 03/27. Useful for academics, professionals in IT industry, educators, students, & anyone involved in AI in the medical field. G Curigliano MD PhD Carmen Criscitiello MIT Critical Data Elsevier
🔜shorturl.at/ckoMQ